Press Releases

Appendix 4C Quarterly Report Quarter Ended 31 March 2015

LEXINGTON, Massachusetts, United States and SYDNEY, Australia–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the...

read more

ENDO Trial Placed on Enrollment Hold

LEXINGTON, Mass & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced today that the U.S. Food and Drug Administration (FDA) has placed a hold on...

read more

Appendix 4C Quarterly Report Quarter ended 31 December 2014

LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 January 2015 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company), a medical device company developing innovative treatments for type 2 diabetes and obesity, is pleased to provide its financial results for the quarter ended...

read more

GI Dynamics Resumes Shipments of EndoBarrier® Product

Notified Body, following review, clears Company to resume shipments LEXINGTON, Massachusetts – 1 December 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that its Notified Body in the European Union, an...

read more

Appendix 4C Quarterly Report Quarter ended 30 September 2014

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Third Quarter 2014 on Tuesday, 4 November 2014 at 5 p.m. U.S. EST / Wednesday, 5 November 2014 at 9 a.m. AEDT LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 31 October 2014 – GI Dynamics, Inc. (ASX: GID) (GI...

read more
Page 6 of 18« First...45678...Last »